Q1 2024 EPS Estimates for Microbot Medical Inc. (NASDAQ:MBOT) Lifted by Analyst

Microbot Medical Inc. (NASDAQ:MBOT) – Equities research analysts at HC Wainwright upped their Q1 2024 earnings per share estimates for Microbot Medical in a report released on Tuesday, April 16th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.17) for the quarter, up from their prior estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.13) EPS and FY2024 earnings at ($0.61) EPS.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01).

Microbot Medical Stock Performance

Shares of NASDAQ MBOT opened at $0.87 on Thursday. Microbot Medical has a 52 week low of $0.86 and a 52 week high of $4.37. The stock has a market capitalization of $12.46 million, a P/E ratio of -0.80 and a beta of 1.64. The stock’s fifty day moving average is $1.19 and its 200 day moving average is $1.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MBOT. Armistice Capital LLC bought a new position in Microbot Medical in the fourth quarter valued at about $2,077,000. Vanguard Group Inc. grew its position in Microbot Medical by 75.8% in the fourth quarter. Vanguard Group Inc. now owns 459,549 shares of the biotechnology company’s stock valued at $754,000 after acquiring an additional 198,213 shares during the last quarter. Renaissance Technologies LLC grew its position in Microbot Medical by 330.0% in the second quarter. Renaissance Technologies LLC now owns 87,695 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 67,300 shares during the last quarter. Bank of New York Mellon Corp grew its position in Microbot Medical by 242.6% in the second quarter. Bank of New York Mellon Corp now owns 52,738 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 37,346 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new position in Microbot Medical in the second quarter valued at about $52,000. Institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.